CanBas Co

CanBas Co Days Payable Outstanding

The Days Payable Outstanding (DPO) of CanBas Co (4575.T) as of Oct 22, 2026 is 0.60. In the previous year, Days Payable Outstanding (DPO) was 53.90 — a change of -98.89% (lower).

Days Payable Outstanding

0.60

YoY

-98.89%

Last updated:

Days Payable Outstanding (DPO) of CanBas Co is 2022 0.60 . Days Payable Outstanding (DPO) of CanBas Co was 2021 53.90 . It decreases by -98.89% lower compared to the previous year.

The CanBas Co Days Payable Outstanding history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Days Payable Outstanding
Date
Days Payable Outstanding
Jan 1, 2014
1.22 JPY
Jan 1, 2016
27.99 JPY
Jan 1, 2017
53.90 JPY
Jan 1, 2022
0.60 JPY
The CanBas Co Days Payable Outstanding history
YEARDays Payable OutstandingYoY
0.60-98.89%
53.90+92.59%
27.99+2,200.22%
1.22—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

CanBas Co Stock analysis

What does CanBas Co do? CanBas Co., Ltd. generates revenue through pharmaceutical research and development, focusing on basic anticancer drug discovery and early clinical development. The company develops drug discovery concepts, selects candidate compounds, conducts simple animal studies, and analyzes basic data on anticancer drug candidates entering development. It also performs preclinical studies for clinical trial applications and manages the initial phase of clinical trials. The primary buyers of these services are pharmaceutical companies seeking to advance their anticancer drug pipelines through early-stage research and development. CanBas Co., Ltd. operates with a team of 12 full-time employees, specializing in anticancer drug research. The company's services are tailored for pharmaceutical firms requiring expertise in early-stage drug development, particularly in the discovery and preclinical phases. Its focus on basic anticancer drug research and early clinical development positions it as a specialized provider in the pharmaceutical R&D sector. The firm's business model relies on providing comprehensive research services to pharmaceutical companies, including concept development, compound selection, animal studies, and data analysis. These services are critical for pharmaceutical firms to progress anticancer drug candidates from discovery to early clinical stages, ensuring efficient and effective development pathways for new treatments. CanBas Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about CanBas Co stock

Days Payable Outstanding (DPO) of CanBas Co is 0.60 in 2022.

Days Payable Outstanding (DPO) of CanBas Co changed from 53.90 to 0.60, representing a -98.89% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Days Payable Outstanding (DPO) CanBas Co since 2006 – with annual values, charts, and detailed analysis.

DPO measures the average number of days a company takes to pay its suppliers. Higher DPO can improve cash flow but may strain supplier relationships.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Days Payable Outstanding (DPO)'s CanBas Co with sector peers and the industry average to assess whether it is attractive.

To evaluate Days Payable Outstanding (DPO)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Days Payable Outstanding (DPO).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Profitability — CanBas Co

ROEROAROCEROICAsset TurnoverInventory TurnoverReceivables TurnoverDays Sales OutstandingDays Inventory OutstandingDays Payable OutstandingCash Conversion CycleCROICGross Profit/AssetsFixed Asset TurnoverEquity TurnoverWorking Capital TurnoverPayables TurnoverCapital IntensityReceivables/RevenueInventory/RevenueEBIT/Assets

All Key Metrics — CanBas Co